Neutropenic enterocolitis in an advanced epithelial ovarian cancer patient treated with paclitaxel/platinum-based chemotherapy: A case report and review of the literature

被引:0
作者
Gadducci, A [1 ]
Gargini, A [1 ]
Palla, E [1 ]
Fanucchi, A [1 ]
Genazzani, AR [1 ]
机构
[1] Univ Pisa, Dept Procreat Med, Div Obstet & Gynecol, I-56127 Pisa, Italy
关键词
neutropenic enterocolitis; ovarian cancer; chemotherapy; paclitaxel;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Literature data show that neutropenic enterocolitis is a rare but severe complication that can occur in cancer patients treated with chemotherapy and especially with taxanes. Case Report: A 60-year-old woman with stage IIIc epithelial ovarian cancer developed neutropenic fever, abdominal pain, severe diarrhoea, nausea, vomiting and oral mucositis one week after the first postoperative cycle of paclitaxel (175 mg/m(2) 3-hour infusion) plus carboplatin-based chemotherapy. Abdominal X-ray showed diffuse dilatation of the ileal and colonic loops with air/fluid. The patient soon recovered after intensive supportive care. For the second cycle the dose of paclitaxel was reduced by 20%, but nine days later the patient again developed severe neutropenia with fever, abdominal colicky pain, diarrhoea and vomiting. The culture of blood samples collected on admission was found to be positive for Escherichia coli, whereas stools resulted negative for both enteric rods and Clostridium difficile toxin. The patient recovered with intensive supportive care, and chemotherapy was continued with single-agent carboplatin. Discussion: The increasing use of paclitaxel in first-line as well as in the salvage treatment of epithelial ovarian cancer could increase the occurrence of neutropenic enterocolitis inpatients with this malignancy. The importance of symptoms such as neutropenic fever; abdominal pain and tenderness and severe diarrhoea should be stressed in patients who receive taxane-based chemotherapy, and intensive supportive care management should be started immediately.
引用
收藏
页码:2509 / 2513
页数:5
相关论文
共 51 条
[41]   Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma [J].
Rose, PG ;
Fusco, N ;
Fluellen, L ;
Rodriguez, M .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1494-1497
[42]   INTESTINAL PERFORATION SECONDARY TO PACLITAXEL [J].
ROSE, PG ;
PIVER, MS .
GYNECOLOGIC ONCOLOGY, 1995, 57 (02) :270-272
[43]  
SEEWALDT V, 1993, J CLIN ONCOL, V11, P1198
[44]   A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer [J].
Seewaldt, VL ;
Cain, JM ;
Goff, BA ;
Tamimi, H ;
Greer, B ;
Figge, D .
GYNECOLOGIC ONCOLOGY, 1997, 67 (02) :137-140
[45]   Colitis associated with docetaxel-based chemotherapy [J].
Sezer, O ;
Eucker, J ;
Possinger, K .
LANCET, 2000, 355 (9217) :1823-1824
[46]  
STELLATO TA, 1989, SEMIN ONCOL, V16, P521
[47]   Gastrointestinal toxicity associated with weekly docetaxel treatment [J].
Stemmler, HJ ;
Kenngott, S ;
Diepolder, H ;
Heinemann, V .
ANNALS OF ONCOLOGY, 2002, 13 (06) :978-981
[48]  
Tashiro M, 2003, AM J GASTROENTEROL, V98, P231
[49]   PACLITAXEL FOR PLATINUM-REFRACTORY OVARIAN-CANCER - RESULTS FROM THE FIRST 1,000 PATIENTS REGISTERED TO NATIONAL-CANCER-INSTITUTE TREATMENT-REFERRAL-CENTER-9103 [J].
TRIMBLE, EL ;
ADAMS, JD ;
VENA, D ;
HAWKINS, MJ ;
FRIEDMAN, MA ;
FISHERMAN, JS ;
CHRISTIAN, MC ;
CANETTA, R ;
ONETTO, N ;
HAYN, R ;
ARBUCK, SG .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (12) :2405-2410
[50]  
Urbach DR, 1999, CAN J SURG, V42, P415